2 results
Approved WMOPending
Primary objectives:• To evaluate the effect of orvepitant once daily on cough severity, as perceived by patients, with IPF• To evaluate the safety of orvepitant once daily in patients with IPFSecondary objectives:• To evaluate the effect of…
Approved WMORecruiting
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…